| Literature DB >> 29684360 |
Sean W Mateer1, Andrea Mathe1, Jessica Bruce1, Gang Liu1, Steven Maltby2, Michael Fricker3, Bridie J Goggins1, Hock L Tay2, Ellen Marks1, Grace Burns1, Richard Y Kim2, Kyra Minahan1, Marjorie M Walker4, Robert C Callister5, Paul S Foster2, Jay C Horvat2, Philip M Hansbro2, Simon Keely6.
Abstract
Inflammatory bowel disease (IBD) is associated with several immune-mediated extraintestinal manifestations. More than half of all IBD patients have some form of respiratory pathology, most commonly neutrophil-mediated diseases, such as bronchiectasis and chronic bronchitis. Using murine models of colitis, we aimed to identify the immune mechanisms driving pulmonary manifestations of IBD. We found increased neutrophil numbers in lung tissue associated with the pulmonary vasculature in both trinitrobenzenesulfonic acid- and dextran sulfate sodium-induced models of colitis. Analysis of systemic inflammation identified that neutrophilia was associated with bacteremia and pyrexia in animal models of colitis. We further identified IL-6 as a systemic mediator of neutrophil recruitment from the bone marrow of dextran sulfate sodium animals. Functional inhibition of IL-6 led to reduced systemic and pulmonary neutrophilia, but it did not attenuate established colitis pathology. These data suggest that systemic bacteremia and pyrexia drive IL-6 secretion, which is a critical driver for pulmonary manifestation of IBD. Targeting IL-6 may reduce neutrophil-associated extraintestinal manifestations in IBD patients.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29684360 DOI: 10.1016/j.ajpath.2018.03.016
Source DB: PubMed Journal: Am J Pathol ISSN: 0002-9440 Impact factor: 4.307